MAYO CLINIC

1-800-533-1710

BCRAB

BCR/ABL1, p210, Quant, Monitor

PATIENT NAME			ORDER NUMBER
TESTINGRNV, INTERFACE			**I109000348**
PATIENT ID SA00119494	DATE OF BIRTH 01/01/1999	SEX Male	REQUESTED BY CLIENT CLIENT
COLLECTED 4/8/2019, 12:00 AM	RECEIVED 4/9/2019, 3:15 PM	REPORTED 4/9/2019, 3:41 PM	
7028846 DLMP Rochester Rochester MN 55901			CLIENT ORDER NUMBER SA00119494 CLIENT MRN SA00119494

Specimen Type	**Peripheral blood**
BCR/ABL1, p210 Result	**see interpretation**

INTERPRETATION

Peripheral blood, BCR/ABL1 mRNA level analysis (p210 fusion form):

Positive. BCR/ABL1 p210 mRNA transcripts were detected and estimated to represent 0.005% of total ABL1 (% BCR/ABL1(p210):ABL1) (MR 4.3).

%BCRABL1 (p210):ABL1 in this assay is reported using the International Scale (IS), in which 0.1% is considered a major molecular response (MMR) in CML (Ref: Baccarani M, et al. Blood;122:872-884; Press RD, et al. J Mol Diagn 2013;15:565-576).

Signing Pathologist: BENJAMIN BAILEY

METHOD

Method summary - BCR/ABL1, p210 fusion: The BCR/ABL1 transcript level was evaluated using a quantitative, reverse transcription PCR. The analytical sensitivity of this assay has been determined at 0.003% (MR 4.5). This assay detects the major breakpoint region-associated common fusion mRNA forms in chronic myelogenous leukemia (e13/a2 and e14/a2), which code for a p210 protein. It is intended for monitoring patients with hematopoietic neoplasms known to carry the p210 fusion form. The assay does not detect other BCR/ABL1 mRNA types, including the e1/a2 transcript (p190 protein) that is commonly present in acute lymphoblastic leukemia. This assay is not intended for use in the diagnostic setting, as it does not detect all BCR/ABL1 mRNA fusion forms. If this has been performed in a diagnostic setting and the result is negative, test: BADX (*BCR/ABL* mRNA Detection, RT-PCR, Qualitative, Diagnostic) should be ordered to evaluate for all possible fusion forms. Please contact the Mayo Molecular Hematopathology Laboratory at 855-516-8404 with questions or if additional testing is required. See the Mayo Clinic Laboratories Interpretive Handbook for method details.

The reproducibility of this assay is such that results within 0.5 log should be considered equivalent. Trends in the level of BCR/ABL1 mRNA should be followed carefully and clinically significant changes in BCR/ABL1 mRNA levels during tyrosine kinase inhibitor (TKI) therapy may indicate the presence of acquired BCR/ABL1 kinase domain mutations, which can be further evaluated using the BCR/ABL KDM assay (test: BAKDM).

DISCLAIMER

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

PATIENT NAME				ORDER NUMBER
TESTINGRNV, INTERFACE				**I109000348**
PATIENT ID SA00119494	DATE OF BIRTH 01/01/1999	SEX Male	REQUESTED BY CLIENT CLIENT	
COLLECTED 4/8/2019, 12:00 AM	RECEIVED 4/9/2019, 3:15 PM	REPORTED 4/9/2019, 3:41 PM		
7028846 DLMP Rochester Rochester MN 55901			CLIENT ORDER NUMBER SA00119494 CLIENT MRN SA00119494	



MAYO CLINIC

1-800-533-1710

BCRAB

BCR/ABL1, p210, Quant, Monitor

PATIENT NAME			ORDER NUMBER
TESTINGRNV, INTERFACE			**I109000348**
PATIENT ID SA00119494	DATE OF BIRTH 01/01/1999	SEX Male	REQUESTED BY CLIENT CLIENT
COLLECTED 4/8/2019, 12:00 AM	RECEIVED 4/9/2019, 3:15 PM	REPORTED 4/9/2019, 3:41 PM	
7028846 DLMP Rochester Rochester MN 55901			CLIENT ORDER NUMBER SA00119494 CLIENT MRN SA00119494

CODE	LABORATORY	ADDRESS			
MCR	Mayo Clinic Laboratories - Rochester Main Campus	200 First Street SW	Rochester	, MN	55905

The collected, received, and reported dates and times on the report are in the time zone of the performing location.